BioNxt Advances Cladribine Thin-Film Development

BioNxt Solutions Inc., a bioscience innovator, has achieved a significant milestone in its drug delivery systems. The company announced the successful formulation of a sublingual thin-film prototype using the active pharmaceutical ingredient cladribine for its clinical candidate, BNT23001, focused on treating multiple sclerosis (MS). Developed in collaboration with Gen-Plus GmbH & Co. KG, these films show promise in drug loading and disintegration, enhancing their potential as a treatment option.

BNT23001 offers an alternative to traditional oral tablets, designed to aid MS patients with swallowing difficulties. The thin-film platform ensures rapid drug absorption, with benefits in bioavailability and patient adherence. BioNxt is also pursuing patent protections across key markets, anticipating further development milestones.

CEO Hugh Rogers highlighted this progress as a pivotal step toward human trials, underscoring the company's readiness for eventual commercialization. The company expects further formulation refinements and anticipates preclinical testing in its journey toward regulatory and market readiness.